NEMBUTAL Drug Patent Profile
✉ Email this page to a colleague
When do Nembutal patents expire, and what generic alternatives are available?
Nembutal is a drug marketed by Akorn, Saptalis Pharms, Epic Pharma Llc, and Rising. and is included in six NDAs.
The generic ingredient in NEMBUTAL is pentobarbital sodium. There are two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the pentobarbital sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Nembutal
A generic version of NEMBUTAL was approved as pentobarbital sodium by SAGENT PHARMS INC on May 23rd, 2016.
Summary for NEMBUTAL
US Patents: | 0 |
Applicants: | 4 |
NDAs: | 6 |
Raw Ingredient (Bulk) Api Vendors: | 37 |
Clinical Trials: | 1 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NEMBUTAL at DailyMed |
Recent Clinical Trials for NEMBUTAL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Washington University School of Medicine | N/A |